Social media

Overwhelmed by the flood of life sciences research? Systematic literature reviews (SLRs) are your toolkit for clarity, credibility, and impact. Learn how to build a strong protocol - Avoid common pitfalls - Apply frame...

We are proud to share that ICON has been recognised by Marksmen Daily as one of India’s Most Preferred Workplaces 2025–26. This award celebrates organisations that foster an environment where people can thrive through c...

ICON has analysed ECG data from over 22,000 healthy volunteers to compare four widely used QT correction formulae. This large-scale study offers new insights into how age and BMI influence QT-interval adjustment – an are...

After a slow start, Project #Optimus is gaining traction among #biotechs. On the latest BioCentury Inc.: This Week podcast, ICON’s Dr Liz O’Brien, Senior Director, Drug Development Solutions, shares expert insights on ho...

The specific needs of oncology clinical trials, alongside the distinct clinical pathway for biosimilars, mean that developing these treatments must be approached very differently from novel biologic development. To under...

In recognition of National Immunisation Month, ICON experts analyse modern vaccine technologies. Learn about nucleic acid-based vaccine technologies, and vaccine delivery systems including viral vectors, virus-like par...

Latest issue out now. If you, like our thousands of subscribers, would like a convenient way to keep on top of the latest regulatory authority updates, sign up to our free newsletter today. Compiled and collated by ICON...

A proactive approach to vaccine long-term follow-up planning enhances data quality and supports evolving regulatory and public expectations for robust safety and effectiveness evidence. ICON’s Dinah Knotts and Ted Wright...

Obesity trials are evolving, and weight alone is no longer enough. Join our live webinar to explore how the complementary tools of COAs + DHTs can deliver richer patient insights, enhancing obesity clinical trials. 📅 O...

Transforming partnerships through flexibility and focus. ​ Discover how ICON helped a sponsor transition to a blended model—combining FSO, FSP and standalone services for greater control and efficiency. https://ow.ly/y3...

Antibody-Drug Conjugates (ADCs) combine potent cytotoxins with selective antibodies for targeted cancer therapy—but their complexity presents major challenges in pharmacokinetics (PK) and bioanalysis. In our latest artic...

ICON is delighted to continue its partnership with the Outsourcing in Clinical Trials Southern California conference taking place 23 – 24 September at the Hyatt Regency La Jolla at Aventine, San Diego, CA. Join us at b...